Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EPC Silver Wound Gel is a topical wound care product containing *nanoparticulate silver* (often as structured or colloidal silver) in a hydrogel base, used for its **antimicrobial properties** in managing minor cuts, abrasions, lacerations, first and second-degree burns, and minor skin irritations. The silver in the gel acts as a broad-spectrum antimicrobial agent, creating a barrier that helps prevent and reduce infection by inhibiting the growth of bacteria and other microorganisms in the wound. The hydrogel formulation both maintains a moist environment optimal for healing and supports autolytic debridement, where the body's own enzymes break down non-viable tissue[2][4][8]. This product is typically available over-the-counter and does not contain antibiotics or sulfa drugs, differentiating it from prescription silver sulfadiazine products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on EPC Silver Wound Gel.